Press ReleaseView printer-friendly version << Back
Novan Creates Dedicated Women’s Health Business Unit
- Business unit will focus on Novan’s proprietary nitric oxide technology and its application to target high-risk human papillomavirus (HPV) and associated cancers affecting women such as cervical cancer where 70% of cases have been conclusively linked to HPV
Novanpartners with Health Decisions, a specialist CRO whose distinctive track record includes managing more than 150 trials in women-only indications
- Previously announced Phase 2 data for the treatment of external genital warts (EGW) provide a specific late stage clinical asset that targets HPV from which this dedicated development unit is launched
- Existing multi-year research collaboration with
University of Alabama-Birminghamextended; recent ground-breaking findings presented at the 2018 International Papillomavirus Conferencein Sydney, Australia, as well as the 49th DNA Tumor Virus Meeting in Madison, Wisconsin
- Exclusive worldwide rights obtained 12 months ago broadens the proprietary nitric oxide technology platform to target certain cancer-causing viruses
Over the past twelve months,
The collaboration with Health Decisions provides
Central to the
Given the global nature, extent and escalation of HPV, as well as the associated infection with a possible cascade to cancer, the interest in this initiative from a variety of sources is significant and emanates from specialized therapeutic and clinical participants, those within the public health sector, in addition to a broad array of non-U.S. countries where prophylactic vaccines are either not available, unaffordable or not permitted.
About Human Papillomavirus
An oncovirus is virus that causes cancer. Approximately 20% of all human cancers, worldwide, are caused by oncoviruses. HPV refers to a large family of double-stranded DNA viruses that induce abnormal growths on the skin or mucosal surfaces. HPV affects nearly 80 million Americans, and an estimated 14 million new cases of the virus are reported each year, according to the
For more information, visit www.Novan.com.
About Health Decisions
Health Decisions is a full-service CRO specializing in women’s health clinical development with a mission to improve healthcare outcomes for women worldwide. Health Decisions has partnered closely with biopharmaceutical companies over the past 29 years to successfully advance their products through the pipeline by leveraging the company’s proven therapeutic and operational experience, high performing women’s health site networks and deep relationships with Key Opinion Leaders. Recognizing that clinical research in women’s health is both an art and a science, Health Decisions offers nimble, tailored solutions rooted in expertise and designed to drive meaningful outcomes for clients, investigators and patients alike.
For more information, visit www.healthdec.com
This press release contains forward-looking statements including, but not limited to, statements related to pharmaceutical development of nitric oxide-releasing product candidates, our intention to advance development of certain product candidates, which is subject to our ability to obtain additional financing or enter into strategic relationships to enable such development, and the future prospects of our business and our product candidates. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from our expectations, including, but not limited to: risks and uncertainties in the clinical development process, including, among others, length, expense, ability to enroll patients, reliance on third parties, and that results of earlier research and preclinical or clinical trials may not be predictive of results, conclusions or interpretations of later research activities or additional trials; risks related to the regulatory approval process, which is lengthy, time-consuming and inherently unpredictable; risks related to the manufacture of clinical trial materials and commercial supplies of any potentially approved product candidates, including the manufacture of our NVN1000 active pharmaceutical ingredient in our primary facility, our internal manufacturing capabilities and our ability to transfer technology and processes as contemplated by the manufacturing agreement; our ability to obtain substantial additional funding for the further advancement and development of our product candidates; our ability to identify and enter into strategic relationships for the further development and potential commercialization of our product candidates; and other risks and uncertainties described in our annual report filed with the
Director, Investor Relations, Capital Sourcing & Relationships
Director, Corporate Communications and Administration